Organon (OGN) Other Non-Current Liabilities (2020 - 2026)
Organon (OGN) posted quarterly Other Non-Current Liabilities of $984.0 million for Q1 2026, down 1.01% year-over-year from $994.0 million in Q1 2025, and down 2.38% on a QoQ basis from $1.0 billion in Q4 2025.
Organon (OGN) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Organon (OGN) has reported Other Non-Current Liabilities for 7 consecutive years, with $984.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 1.01% year-over-year to $984.0 million; the TTM figure through Mar 2026 stood at $984.0 million (down 1.01% YoY), while the FY2025 annual figure was $1.0 billion, up 3.17% from the prior year.
- Other Non-Current Liabilities came in at $984.0 million for Q1 2026 at Organon, down from $1.0 billion in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $1.1 billion in Q3 2025, with the low at $393.0 million in Q2 2023.
- Average Other Non-Current Liabilities over 5 years is $669.3 million, with a median of $548.0 million recorded in 2024.
- Across the five-year window, Other Non-Current Liabilities tumbled 75.42% in 2022 and soared 137.14% in 2024, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $411.0 million in 2022, then climbed by 0.24% to $412.0 million in 2023, then jumped by 137.14% to $977.0 million in 2024, then rose by 3.17% to $1.0 billion in 2025, then slipped by 2.38% to $984.0 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $984.0 million, $1.0 billion, and $1.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 984.00 Mn |
| Dec 31, 2025 | 1.01 Bn |
| Sep 30, 2025 | 1.12 Bn |
| Jun 30, 2025 | 1.12 Bn |
| Mar 31, 2025 | 994.00 Mn |
| Dec 31, 2024 | 977.00 Mn |
| Sep 30, 2024 | 674.00 Mn |
| Jun 30, 2024 | 548.00 Mn |
| Mar 31, 2024 | 549.00 Mn |
| Dec 31, 2023 | 412.00 Mn |
| Sep 30, 2023 | 421.00 Mn |
| Jun 30, 2023 | 393.00 Mn |
| Mar 31, 2023 | 421.00 Mn |
| Dec 31, 2022 | 411.00 Mn |
| Sep 30, 2022 | 441.00 Mn |
| Jun 30, 2022 | 448.00 Mn |
| Mar 31, 2022 | 454.00 Mn |
| Dec 31, 2021 | 463.00 Mn |
| Sep 30, 2021 | 506.00 Mn |
| Jun 30, 2021 | 487.00 Mn |